Dermatology

This site is intended for healthcare professionals only

Login Register

MD Brand Connect
Vaccine Hub
MDTV
Fact Check
Health Dialogues

Medical News & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry
MDTV

This site is intended for healthcare professionals only

Login Register

LoginRegister

Home
Medical news & Guidelines
Health news
Fact Check
AYUSH
State News
Medical Education
Industry

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Home

Ruchika Sharma

Articles By : Ruchika Sharma

Phase 3 data shows Covaxin 77.8 percent effective against Covid-19, says Lancet

Ruchika Sharma13 Nov 2021 11:46 AM IST

Hyderabad: Bharat Biotech has recently announced that the safety and efficacy analysis data from Phase III clinical trials of COVAXIN is peer...

Hester India to acquire 50 percent stake in Thrishool Exim for Rs 16 crore

Ruchika Sharma13 Nov 2021 11:00 AM IST

New Delhi: Hester India has recently announced that the company has entered into an agreement to acquire 50% stake in Thrishool Exim Limited, ...

Alzheimer's drug price will be competitive: Roche executive

Ruchika Sharma13 Nov 2021 10:00 AM IST

New Delhi: Roche Holding AG, still months away from seeking regulatory approval of its experimental Alzheimer's drug, is already taking aim at rival...

Aurobindo Pharma gets USFDA OAI status for API facility in Hyderabad

Ruchika Sharma12 Nov 2021 2:33 PM IST

Hyderabad: Drugmaker, Aurobindo Pharma, has recently announced that the company has received Official Action Indicated (OAI) status...

Cipla resolves funding dispute with Pulmatrix over asthma drug Pumazole

Ruchika Sharma12 Nov 2021 1:31 PM IST

Pulmazole is an inhaled iSPERSE formulation of the antifungal drug itraconazole for the treatment of allergic bronchopulmonary aspergillosis (ABPA) in...

Sun Pharma to launch Molnupiravir under brand name Molxvir in India

Ruchika Sharma12 Nov 2021 12:00 PM IST

Mumbai: Sun Pharmaceutical Industries Limited has recently said that the company is gearing up to introduce Merck Sharpe Dohme (MSD) and Ridgeback's...

Novo Nordisk India signs Kapil Dev as brand ambassador for diabetes awareness

Ruchika Sharma12 Nov 2021 11:00 AM IST

New Delhi: Novo Nordisk India on Tuesday announced Kapil Dev as their brand ambassador and an embodiment of the company's core value of driving change...

PharmEasy files for Rs 62.50 billion IPO

Ruchika Sharma12 Nov 2021 10:00 AM IST

Bengaluru: Indian digital healthcare platform PharmEasy filed on Wednesday for an initial public offering (IPO) of up to 62.50 billion rupees ($842.43...

Pfizer -BioNtech seeks USFDA nod for COVID vaccine boosters for adults

Ruchika Sharma12 Nov 2021 9:30 AM IST

New Delhi: Pfizer Inc and BioNTech on Tuesday requested the U.S. Food and Drug Administration (FDA) to authorize booster doses of their COVID-19...

Alembic Pharma gets 10 USFDA observations for Karkhadi facility

Ruchika Sharma11 Nov 2021 2:47 PM IST

Vadodara: Drugmaker, Alembic Pharmaceuticals, has recently announced that the United States Food and Drug Administration (USFDA) has issued Form 483...

Zydus Cadila bags USFDA nod for Glycopyrrolate Injection

Ruchika Sharma11 Nov 2021 12:00 PM IST

Ahmedabad: Pharma major , Zydus Cadila, has recently announced that the company has received final approval from the U.S. Food and Drug Administration...

Shortage of 2 billion syringes in 2022, warns WHO

Ruchika Sharma11 Nov 2021 11:00 AM IST

Geneva: The World Health Organization (WHO) warned Tuesday there could be shortfall of up to two billion syringes in 2022, which threatens to hamper...

Powered By: Hocalwire

X

We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok